Chronic Obstructive Pulmonary Disease clinical trials at UC Irvine
1 research study open to eligible people
Showing trials for
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation
open to eligible people ages 40-80
Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.
Newport Beach, California and other locations
Our lead scientists for Chronic Obstructive Pulmonary Disease research studies include Lillian Chow.
Last updated: